Fuisz Pharma LLC Announces Allowance of Patent Claims by the Japan Patent Office Relating to the Programming of Bodily Fluid Analyzers

Sep 16, 2013, 08:00 ET from Fuisz Pharma LLC

MIAMI, Sept. 16, 2013 /PRNewswire-USNewswire/ -- Fuisz Pharma LLC announced today that the Japan Patent Office has allowed claims in a patent case that parallels US 7,824,612 ("Bodily fluid analyzer, and system including same and method for programming same").

Richard C. Fuisz, M.D., commented:  "The allowance of parallel claims in Japan underscores the novelty of the '612 art, which enables a physician to set patient specific analyte threshold values, programming these physician set values onto a bodily fluid analyzer, and generating alert levels from a bodily fluid analyzer."

This allowance is an important addition to our current portfolio of diagnostic art, which includes the '612, and two separate pending applications.   One of these pending applications address the consolidation, interpretation and presentation of data from bodily fluid analyzers.  That means doctor friendly data.   We cannot substitute algorithmic-driven server based conclusions for the doctor's art.  The second is a novel system directed to the promising field of breath-based diagnostics."

Dr. Richard Fuisz is founding member of Fuisz Pharma LLC (http://en.wikipedia.org/wiki/Richard_Fuisz).

Joseph Fuisz, Managing Member of Fuisz Pharma LLC, stated: "The '612 patent has been subject to litigation brought by plaintiffs Elizabeth Holmes and Theranos (www.theranos.com) in the United States District Court for Northern California ( 5:11-cv-05236-PSG).  A related action brought by Elizabeth Holmes and Theranos against a separate defendant in DC Superior Court was dismissed by Judge Craig Iscoe (2012 CA 009617 M).   Fuisz Pharma LLC is confident it will prevail on the merits including on certain bases analogous to those cited by Judge Iscoe in his dismissal Order."

Fuisz Pharma LLC is a private pharmaceutical technology company originated by the Fuiszes. The Fuiszes have made substantial contributions in drug delivery including orally dissolving tablets and novel particle coating systems at Fuisz Technologies; inventing and developing thin film drug delivery technologies at Kosmos Pharma and MonoSol Rx, as well as independently developing extruded sheet technology, and have extensive experience working with big and specialty pharma.  Fuisz Pharma is also active in diagnostic systems.  Fuisz Pharma has its headquarters in Miami. www.fuisz.com.

SOURCE Fuisz Pharma LLC